Recently, Class 1 tumours have been subdivided into two subgroups, Class 1A (2% of patients 5‐year metastatic risk) and Class 1B (21% of patients 5‐year metastatic risk) 125, based on the differential expression of CDH1 and RAB31. Class 1A tumours are also associated with D3 and EIF1AX mutations. Here, EIF1AX is linked to neoplasm.